| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |
From the Institute for Cellular and Molecular Biology,*
the Instituto de Ciências Biomédicas Abel
Salazar,
and the Hospital Geral de Santo
António,
Porto, Portugal
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The cellular effects of TTR deposition on neuronal function in FAP
remain however to be elucidated. In the case of Alzheimer’s disease,
the receptor for advanced glycation end products has been associated
with neural toxicity.5
We have previously shown that TTR
fibrils are able to bind receptor for advanced glycation end products,
triggering nuclear factor (NF)-
B activation.6
However,
in FAP no detailed immunohistochemical studies exist on the
relationship between amyloid deposition and neurodegeneration. In the
present work we investigated in which form TTR is deposited in the
nerve, early in FAP, before major nerve fiber degeneration and assessed
cytotoxic effects of different stages of TTR fibrillogenesis both
in vitro and in vivo.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Sural nerve biopsy specimens from asymptomatic members of FAP kindreds, from FAP patients as well as normal controls were available in Hospital Geral de Santo Antonio, Porto, Portugal, because this material was obtained as part of the clinical diagnosis and evaluation of polyneuropathy in Portugal, during the period of 1979 to 1989, before the current use of less invasive methods. Initial characterization of clinical material included morphometric studies of nerve fiber density and abundance of amyloid deposits. Amyloid deposition was assessed by standard Congo Red staining and was scored from 0 to 3 depending on the amount of amyloid deposits found (0, no amyloid deposition; 1, discrete amyloid deposition; 2, mildly abundant deposition; and 3, very abundant deposition). Patients were scanned for the Val30Met mutation by immunoblotting.7 Morphometric studies were performed on sural nerve biopsy tissue fixed in glutaraldehyde (2.5%) in 0.1 mol/L cacodylate buffer (pH 7.4), postfixed in osmium tetroxide, and embedded in Epon. Quantitation of MFs in semithin sections was performed in an area of at least 0.1 mm2 at a magnification of x1000. Myelinated fibers (MFs) were counted, their diameters measured, and the density was calculated. Unmyelinated fibers (UFs) were counted from thin sections in an area of at least 0.005 mm2 and their densities calculated. Evaluation for typical symptoms of FAP8 was performed, namely by assessment of sensory impairment.
Immunohistochemistry
For immunohistochemistry, nerve paraffin sections were deparaffinated, dehydrated in a modified alcohol series, and incubated in blocking buffer [1% bovine serum albumin (BSA), and 4% horse serum in phosphate-buffered saline (PBS)] for 30 minutes at 37°C in a moist chamber. Subsequently, incubation with primary antibody at the appropriate dilution in blocking buffer was performed overnight at 4°C. The primary antibodies used were: rabbit polyclonal anti-TTR IgG (1:300; DAKO, Glostrup, Denmark), goat polyclonal anti-macrophage colony-stimulating factor (MCSF) IgG (1:25; Santa Cruz Biotechnology, Santa Cruz, CA) and polyclonal rabbit anti-neurofilament 200 IgG (1:200; Sigma, Sintra, Portugal). Antigen visualization was performed with either the biotin-extravidin-alkaline phosphatase kits or with the biotin-extravidin-peroxidase kits (Sigma), using Fast Red (Sigma) or 3-amino-9-ethyl carbazole (Sigma), respectively, as substrates. On parallel control sections, primary antibody was replaced by blocking buffer. Semiquantitative analysis of immunohistochemical images was performed with the Universal Imaging system (NIH). Results shown represent percent occupied area ±SD.
Immunogold Labeling
Thin sections of glutaraldehyde-osmium tetroxide-fixed, Epon-embedded nerves were mounted onto nickel grids, treated with 14.4% sodium metaperiodate for 30 minutes, and subsequently blocked with blocking buffer (1% BSA in PBS) for 30 minutes. Anti-human TTR (DAKO) was used as primary antibody diluted 1:100 in blocking buffer. In parallel control sections antibody preadsorbed with TTR (1 µg of TTR/100 µl diluted primary antibody incubated overnight at room temperature) was used. As secondary antibody, goat anti-rabbit immunoglobulins coupled to 10-nm gold particles (Amersham, Freiburg, Germany), diluted 1:15 in blocking buffer, were used for 45 minutes at room temperature. The grid was subsequently washed in 10% BSA, 3% NaCl, 5% fetal bovine serum, and 0.05% Tween 20 in PBS, four times for 10 minutes each. Finally sections were stained with uranyl acetate for 3 minutes and lead citrate for 40 seconds.
Isolation and Purification of TTR; Preparation of Amyloid Fibrils
Recombinant TTR (either wild type or mutant TTR Leu55Pro) was produced in an Escherichia coli expression system, isolated, and purified as previously described.9 For preparation of amyloid fibrils, mutant TTR was dialyzed against water, pH 7.0, and concentrated to 5 mg/ml. At this point the preparation was centrifuged at 15,000 x g for 30 minutes at 4°C. Subsequently, the pellet was washed and resuspended in PBS, pH 7.4, at 2 mg/ml and incubated at 37°C. At given time points (t = 1, t = 6, and t = 15 days), samples were visualized for the presence of amyloid fibrils by transmission electron microscopy (TEM). All preparations were positive by Thioflavin T spectrofluorometric assays. Protein concentration was determined by the Lowry method.
Transmission Electron Microscopy
For visualization by TEM (60 kV; Zeiss), samples were adsorbed to glow-discharged carbon-coated collodion film on 400-mesh copper grids. For negative staining, grids were washed with deionized water and stained with 0.75% uranyl acetate.
Caspase-3 Assay
RN22 cells (rat Schwannoma cell line) were propagated in 25-cm2 flasks and maintained at 37°C in a humidified atmosphere of 95% and 5% CO2. Cells were grown in Dulbecco’s minimal essential medium supplemented with 10% fetal bovine serum (Life Technologies, Inc., Barcelona, Spain).
Activation of caspase-3 was measured using the CaspACE colorimetric 96-well plate assay system (Promega), following the manufacturer’s instructions. Briefly, 80% confluent cells in Dulbecco’s minimal essential medium with 1% fetal bovine serum were exposed for 48 hours to 2 µmol/L of TTR (either soluble or fibrillar mutant TTR). Subsequently, each well was trypsinized and the cell pellet was lysed in 100 µl of hypotonic lysis buffer (Promega, Madison, WI) by four cycles of freeze/thawing. Forty µl of each cell lysate was used in duplicates for determination of caspase-3 activation. The remaining cell lysate was used to measure total cellular protein concentration with the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA), using BSA as standard. Values shown are the mean of duplicates and the experiment was performed three times.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
As no systematic immunohistochemical data existed relating TTR
deposition and FAP progression, we started by assessing nerves from
asymptomatic Val30Met carriers and FAP patients in different stages of
disease progression; TTR deposition by immunohistochemistry and amyloid
presence by Congo Red staining were investigated. The scoring system of
patients material was performed by morphometric measurements of MFs and
UFs and is summarized in Table 1
.
|
10,000 fibers/mm2; UFs varied from
30,000 to 70,000 fibers/mm2) and no fiber
degeneration was found. FAP 1 patients (n = 4)
had a discrete reduction (MFs varied between 7000 and 2000
fibers/mm2; UFs varied between 4000 and 40,000
fibers/mm2) and presented already TTR amyloid
deposition in the nerve and fiber degeneration in contrast to FAP 0.
Two of the FAP 1 patients studied here were asymptomatic at the time of
biopsy. FAP 2 patients (n = 4) showed evident
reduction (MFs 1000 fibers/mm2; UFs <10,000
fibers/mm2); and finally, FAP 3 patients
(n = 3) presented severe reduction (MFs <1000
fibers/mm2; UFs absent). FAP 2 and FAP 3 patients
were all symptomatic and amyloid deposition was in most instances
inversely proportional to nerve fiber density.
We observed that in the stage before loss of UFs and MFs and major
nerve fiber degeneration (FAP 0), despite the absence of Congo Red
birefringence (the hallmark of amyloid) TTR was present in all 12 cases
investigated as revealed by immunohistochemistry with an anti-TTR
antibody (Figure 1A
, middle left). It is
interesting to note that up to 22 years after detection of TTR
deposition in the nerve in a nonamyloid form (such as the case of
patient 1), no clinical symptoms of FAP were observed. The specificity
of the TTR staining was demonstrated by the fact that no TTR deposition
occurred in nerves from normal individuals (Figure 1A
, top left) and
also because no staining was revealed when the anti-TTR antibody was
preadsorbed with TTR (data not shown). We hypothesized that TTR might
deposit in a nonfibrillar form in early stages of FAP, before
assembling into amyloid fibrils, that give the characteristic
green-birefringence by Congo Red staining, as observed in stages FAP 1
to 3 (Figure 1A
, bottom right).
|
To further assess the nature of the deposited TTR in FAP 0
patients, we performed electron microscopy and TTR immunogold labeling
of FAP 0 (n = 2), FAP 1
(n = 1), and FAP 3 (n =
1) nerves. In FAP 0 patients, immunolabeling was observed
extracellularly in the proximity of SCs, in a nonfibrillar form, as
evidenced in Figure 1B
by arrows (left panel); very small contiguous
fibrillar-like assemblies were noticed, most likely too small to give
birefringence with Congo Red staining on histochemistry (Figure 1A
,
middle right). To ascertain the specificity of the immunogold labeling,
we performed similar labeling of normal control nerves. In areas
corresponding to sites of TTR deposition in FAP 0 patients, ie, in the
extracellular matrix near collagen fibrils, no labeling could be
observed in control nerves (not shown). In the FAP 3 patient, the
labeled material was clearly present in a fibrillar form (Figure 1B
,
middle panel) and the dimensions of the fibrils (8 to 10 nm) were
typical of amyloid fibrils. When we performed similar gold immunogold
labeling using preadsorbed anti-TTR in the same FAP 3 nerve, no
labeling was observed, thus showing the specificity of our results
(Figure 1B
, right). In FAP 1, both forms of deposition, ie,
nonfibrillar and fibrillar were detected (not shown).
Nerve Cytotoxicity of Nonfibrillar TTR in Early Stages of FAP
To assess the possible cytotoxicity of nonfibrillar TTR deposits
and because previous studies demonstrated activation of NF-B by TTR
in FAP tissues,6
we assessed cellular stress in
early-stage FAP. Because NF-B activation might cause increased
expression of proinflammatory cytokines, namely MCSF, we analyzed the
presence of MCSF in affected nerves from FAP patients in relation to
deposition of TTR.
Semiquantitative analysis of immunohistochemical images for
immunoreactive MCSF in FAP nerve biopsies, compared with control
individuals, demonstrated early an increased expression of this
cytokine (Figure 2)
. Although normal nerve showed virtually no
detectable antigen (Figure 2
, top right), FAP 0 individuals (ie, before
amyloid was present) already displayed increased MCSF
antigens (Figure 2
, top left). Increased
levels of this cytokine were also evident in FAP 3 individuals (Figure 2
, top middle panel). In each case, the level of cytokine appeared to
increase by approximately twofold, compared with controls, and
was statistically significant (Figure 2
, bottom right)
(P < 0.03). Endoneurial axons seemed
responsible for this increase in MCSF expression based on
co-localization with the neuron-specific marker N200 (Figure 2
, bottom
left). The presence of an inflammation marker in FAP 0 nerves suggests
that nonfibrillar TTR deposition is already cytotoxic.
|
TTR Leu55Pro is associated with a very aggressive form of FAP and
X-ray data on this mutant revealed important structural changes that
might be representative of amyloid precursor forms;10
this
variant thus constitutes an important tool to follow fibrillogenesis.
We studied TTR Leu55Pro fibril dynamic assembly throughout time at
physiological conditions (PBS, pH 7.4) by TEM and tested the toxicity
of the different species formed during that process. After 1 day we
could observe aggregates and very short prefibrillar structures 7 to 8
nm wide (Figure 3A
, top right). Longer
incubations at 37°C showed that these structures elongated and formed
fibrils with widths of 8 nm (Figure 3A
, bottom panels)
morphologically similar to amyloid fibrils present in FAP amyloid
deposits.
|
. These results confirm that nonfibrillar TTR is
already toxic. Furthermore, our results showed that mature amyloid
fibrils are not toxic for the cell line used. |
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
A previous study11 of 31 FAP asymptomatic carriers was conducted, in which sural nerve biopsies were assessed for amyloid deposition, for the presence of degenerating fibers and morphometric studies of UFs and MFs. Half of the asymptomatic carriers already presented amyloid deposition and/or fiber degeneration. No clear relationship between the amount of endoneurial amyloid deposition and degree of fiber loss was observed in these individuals. Also, no evidence of nerve fiber degeneration caused by close contact with amyloid deposits was demonstrated. Therefore, there seems to be no cause-effect relationship between amyloid deposition and FAP, suggesting the importance of other factors in this disorder and/or of toxicity of small preamyloid aggregates of TTR.
In this report we show deposition of TTR in the form of small toxic nonfibrillar aggregates occurring locally before amyloid formation. Individuals with this nonfibrillar form of TTR deposition (FAP 0) are asymptomatic, have normal fiber density, and no fiber degeneration. It is interesting to note that in some FAP 0 patients, even 11 to 22 years after detection of nonfibrillar TTR in the nerve, no clinical symptoms related to FAP are detected. Given the demonstrated toxic nature of these small aggregates, the mechanism by which axons are able to survive this injury should be further addressed in the future.
Our data indicates that neuronal stress in patients with FAP begins at
a very early stage; increased expression of MCSF in peripheral nerve
axons was observed before amyloid deposits were detected based on Congo
Red staining (FAP 0). The increased expression of MCSF is probably
related to the previously reported activation of NF-B by TTR fibrils
and up-regulation of p50, one of the NF-B subunits, in FAP
nerves,6
as MCSF is one of the targets of the NF-B
transcription factor.12
We further demonstrated the cytotoxicity of prefibrillar TTR structures in cell culture assays by determining the activation of caspase-3. Supporting the concept of toxicity of nonfibrillar TTR found by immunohistochemistry, caspase-3 activation occurred only with the initial TTR aggregates and not with the soluble protein and longer fibrils. This observation resembles other amyloid-related disorders such as Alzheimer’s disease. In Alzheimer’s disease, the mean level of soluble Aß is increased and correlates highly with markers of disease severity.13,14 In contrast, the level of insoluble Aß is found only to discriminate Alzheimer’s disease patients from controls13 and does not correlate with disease severity or number of amyloid plaques. These findings supported the concept of several interacting pools of Aß: a large relatively static insoluble pool that is derived from a constant turning over of the smaller soluble pool.13 In the case of FAP, it has been shown that soluble TTR plasma levels are decreased in patients,15 despite an equal expression in the liver.16 Whether this decrease is because of the extracellular deposition of the mutated protein or an altered metabolism remains to be elucidated.
TTR is synthesized mainly by the liver and the choroid plexus of the brain,17 but not by the nerve, its major site of deposition. It is presently not known whether the deposited TTR derives from the plasma pool, of liver origin, and/or from the cerebrospinal fluid pool, originated by the choroid plexuses of brain, neither the mechanisms by which TTR crosses these barriers. It is possible that sensory and sympathetic nerve ganglion cells and their axons are probably constantly exposed to serum or cerebrospinal fluid proteins, even in normal cases and this fact would account for TTR access to the nerve.
The reason why this protein preferentially aggregates in this environment is however not known. TTR is a tetrameric protein of four identical subunits.18 The molecular mechanisms that convert soluble TTR tetramers into insoluble amyloid fibrils are still unknown. Dissociation of the tetramer is thought to be a prerequisite for amyloid formation in vitro and involvement of monomers and/or dimers in fibril formation has been suggested.19,20 Quintas and colleagues21 observed that on dilution, at TTR concentrations compatible with the interstitial milieu where aggregation occurs, tetrameric TTR dissociates into monomeric species that then aggregate.
The close association of TTR aggregates and amyloid fibrils with SCs observed in FAP1 might result in cellular activation and altered gene expression, as we document here for the case of MCSF. In axons of Guilliain-Barre syndrome, another form of peripheral neuropathy, increased expression of molecules implicated in immune-mediated processes, such as cytokines, has already been reported.22 We hypothesize that despite the apparent lack of a primary direct deleterious effect on the SC itself, subsequent axonal degeneration may occur as a consequence of the disturbed axon-SC interaction. Interactions of SCs and axons have been the focus of much attention in other neuropathies such as Charcot-Marie-Tooth disorders.23 It is well known that disturbed SC-axon crosstalk has an high impact on the normal physiology and survival of these two cell types. It is possible that in FAP, as a consequence of the toxicity of nonfibrillar TTR in contact with SCs, abnormal SC-axon interactions ultimately occur reflecting the pathophysiological changes associated with this disorder. However, further studies are needed to address this issue.
The study here reported is relevant to understanding molecular events leading to neurodegeneration in FAP, and as a model for neurodegeneration in other peripheral axonal neuropathies.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by grants from PRAXIS XXI (35785/99 and 35735/99) and fellowships BPD/22027/99 (to M. M. S.), BD/15725/98 (to I. C.), BTI/PL21902 (to R. F.) from the Fundação para a Ciência e Tecnologia from Portugal.
Accepted for publication August 31, 2001.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  E. Herczenik and M. F. B. G. Gebbink Molecular and cellular aspects of protein misfolding and disease FASEB J, July 1, 2008; 22(7): 2115 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Reixach, T. R. Foss, E. Santelli, J. Pascual, J. W. Kelly, and J. N. Buxbaum Human-Murine Transthyretin Heterotetramers Are Kinetically Stable and Non-amyloidogenic: A LESSON IN THE GENERATION OF TRANSGENIC MODELS OF DISEASES INVOLVING OLIGOMERIC PROTEINS J. Biol. Chem., January 25, 2008; 283(4): 2098 - 2107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stefani Generic Cell Dysfunction in Neurodegenerative Disorders: Role of Surfaces in Early Protein Misfolding, Aggregation, and Aggregate Cytotoxicity Neuroscientist, October 1, 2007; 13(5): 519 - 531. [Abstract] [PDF]
|
|
|
|
 |
|
 N. D. Hammer, J. C. Schmidt, and M. R. Chapman The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization PNAS, July 24, 2007; 104(30): 12494 - 12499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang and J. Robbins Heart Failure and Protein Quality Control Circ. Res., December 8, 2006; 99(12): 1315 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Dember Amyloidosis-Associated Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3458 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. KIM and R. TAKAHASHI Role of Polyunsaturated Fatty Acids for Misfolding Protein Aggregations: Implication for Neurodegenerative Diseases Ann. N.Y. Acad. Sci., November 1, 2006; 1086(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Teixeira, F. Cerca, S. D. Santos, and M. J. Saraiva Endoplasmic Reticulum Stress Associated with Extracellular Aggregates: EVIDENCE FROM TRANSTHYRETIN DEPOSITION IN FAMILIAL AMYLOID POLYNEUROPATHY J. Biol. Chem., August 4, 2006; 281(31): 21998 - 22003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pieri, M. Bucciantini, D. Nosi, L. Formigli, J. Savistchenko, R. Melki, and M. Stefani The Yeast Prion Ure2p Native-like Assemblies Are Toxic to Mammalian Cells Regardless of Their Aggregation State J. Biol. Chem., June 2, 2006; 281(22): 15337 - 15344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Novitskaya, O. V. Bocharova, I. Bronstein, and I. V. Baskakov Amyloid Fibrils of Mammalian Prion Protein Are Highly Toxic to Cultured Cells and Primary Neurons J. Biol. Chem., May 12, 2006; 281(19): 13828 - 13836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cardoso and M. J. Saraiva Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model FASEB J, February 1, 2006; 20(2): 234 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cecchi, S. Baglioni, C. Fiorillo, A. Pensalfini, G. Liguri, D. Nosi, S. Rigacci, M. Bucciantini, and M. Stefani Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates J. Cell Sci., August 1, 2005; 118(15): 3459 - 3470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lindgren, K. Sorgjerd, and P. Hammarstrom Detection and Characterization of Aggregates, Prefibrillar Amyloidogenic Oligomers, and Protofibrils Using Fluorescence Spectroscopy Biophys. J., June 1, 2005; 88(6): 4200 - 4212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Morais-de-Sa, P. J. B. Pereira, M. J. Saraiva, and A. M. Damas The Crystal Structure of Transthyretin in Complex with Diethylstilbestrol: A PROMISING TEMPLATE FOR THE DESIGN OF AMYLOID INHIBITORS J. Biol. Chem., December 17, 2004; 279(51): 53483 - 53490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bucciantini, G. Calloni, F. Chiti, L. Formigli, D. Nosi, C. M. Dobson, and M. Stefani Prefibrillar Amyloid Protein Aggregates Share Common Features of Cytotoxicity J. Biol. Chem., July 23, 2004; 279(30): 31374 - 31382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koike, K. Misu, M. Sugiura, M. Iijima, K. Mori, M. Yamamoto, N. Hattori, E. Mukai, Y. Ando, S. Ikeda, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy Neurology, July 13, 2004; 63(1): 129 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. MacRaild, C. R. Stewart, Y.-F. Mok, M. J. Gunzburg, M. A. Perugini, L. J. Lawrence, V. Tirtaatmadja, J. J. Cooper-White, and G. J. Howlett Non-fibrillar Components of Amyloid Deposits Mediate the Self-association and Tangling of Amyloid Fibrils J. Biol. Chem., May 14, 2004; 279(20): 21038 - 21045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Korenaga, X. Fu, Y. Xing, T. Matsusita, K. Kuramoto, S. Syumiya, K. Hasegawa, H. Naiki, M. Ueno, T. Ishihara, et al. Tissue Distribution, Biochemical Properties, and Transmission of Mouse Type A AApoAII Amyloid Fibrils Am. J. Pathol., May 1, 2004; 164(5): 1597 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Plakoutsi, N. Taddei, M. Stefani, and F. Chiti Aggregation of the Acylphosphatase from Sulfolobus solfataricus: THE FOLDED AND PARTIALLY UNFOLDED STATES CAN BOTH BE PRECURSORS FOR AMYLOID FORMATION J. Biol. Chem., April 2, 2004; 279(14): 14111 - 14119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Reixach, S. Deechongkit, X. Jiang, J. W. Kelly, and J. N. Buxbaum Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture PNAS, March 2, 2004; 101(9): 2817 - 2822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Merlini and V. Bellotti Molecular Mechanisms of Amyloidosis N. Engl. J. Med., August 7, 2003; 349(6): 583 - 596. [Full Text] [PDF]
|
|
|
|
|
|
I. CARDOSO, G. MERLINI, and M. J. SARAIVA 4'-iodo-4'-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters FASEB J, May 1, 2003; 17(8): 803 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Sousa, R. Fernandes, J. A. Palha, A. Taboada, P. Vieira, and M. J. Saraiva Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Human Transthyretin Leu55Pro Am. J. Pathol., November 1, 2002; 161(5): 1935 - 1948. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
